VUMERITY

VUMERITY. VUMERITY is an oral medication approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is a novel fumarate prodrug of monomethyl fumarate (MMF), designed to offer an improved gastrointestinal tolerability profile compared to its predecessor, dimethyl fumarate (sold as Tecfidera). The medication is developed and marketed by Biogen, a global biotechnology company based in Cambridge, Massachusetts.

Medical uses

VUMERITY is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, a chronic autoimmune disease of the central nervous system. Its approval by the U.S. Food and Drug Administration (FDA) in October 2019 was based on data demonstrating its bioequivalence to dimethyl fumarate in delivering the active metabolite, monomethyl fumarate, into the bloodstream. Clinical studies, including the pivotal EVOLVE-MS-2 trial, showed that VUMERITY provides similar efficacy in reducing annualized relapse rates and MRI lesions while significantly reducing the incidence and severity of certain gastrointestinal side effects. Treatment decisions often involve neurologists at institutions like the Cleveland Clinic or the Mayo Clinic, considering a patient's disease activity and tolerance to other disease-modifying therapies.

Adverse effects

The most common adverse reactions associated with VUMERITY involve the gastrointestinal tract, including flushing, abdominal pain, diarrhea, and nausea; however, their frequency and severity are generally lower than with dimethyl fumarate. Serious but rare risks include lymphopenia (low lymphocyte counts), which requires monitoring via complete blood count tests, and a potential increased risk for progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection caused by the JC virus. Other potential complications can involve hepatotoxicity and severe allergic reactions, prompting warnings from regulatory bodies like the European Medicines Agency (EMA) and the FDA.

Pharmacology

VUMERITY (diroximel fumarate) is a prodrug that is rapidly converted by esterase enzymes in the intestine and plasma to its active metabolite, monomethyl fumarate (MMF). The primary mechanism of action involves MMF activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which leads to an antioxidant and anti-inflammatory response within the central nervous system. This pharmacological action is believed to protect neurons and glial cells from damage caused by oxidative stress and immune attacks, a hallmark of multiple sclerosis pathology. The drug's pharmacokinetics are characterized by a short half-life, with peak plasma concentrations of MMF occurring approximately 2.5 to 3 hours after oral administration.

Society and culture

The development and marketing of VUMERITY by Biogen occurred within a competitive landscape for multiple sclerosis treatments, which includes other oral agents like fingolimod (Gilenya) and teriflunomide (Aubagio). Its introduction was positioned as providing a therapeutic option with a potentially improved side-effect profile, addressing a significant unmet need for patient tolerability. The cost of the drug and its coverage by health insurers and programs like Medicare and Medicaid are subjects of ongoing discussion in the United States healthcare system. Patient advocacy groups, such as the National Multiple Sclerosis Society, often provide resources and information regarding access to newer therapies like VUMERITY.

History

The discovery pathway for VUMERITY originated from research into fumaric acid esters, which have a long history of use for psoriasis treatment in Europe. Building on the clinical and commercial success of dimethyl fumarate (Tecfidera), which was approved by the FDA in 2013, scientists at Alkermes plc collaborated with Biogen to develop a prodrug with an improved tolerability profile. The compound diroximel fumarate was subsequently acquired by Biogen. Following positive results from the phase III EVOLVE-MS-2 study, which met its primary endpoint of reduced gastrointestinal symptoms, the drug received regulatory approval from the FDA in 2019 and later from Health Canada and the EMA.

Category:Drugs